Improving the Quality of Life of Latin American Patients
M8 provides healthcare professionals and patients with access to proven treatments they need to thrive. We serve as a comprehensive source of expertise in each of the following therapeutic areas.
Central Nervous System
Oncology & Hematology
Reliable, Convenient Service and Support for Professionals and Patients
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Our Commitment to Latin America
Six core values guide us on our mission to provide support to the patients and healthcare professionals of Latin America.
RISPERDAL® is indicated for the treatment of a wide range of patients with schizophrenia, including first-episode psychosis, acute exacerbation of schizophrenia, chronic schizophrenia, and other psychotic conditions with positive signs (hallucinations, delusions, illusions, thought disturbances, hostility) and/or negative symptoms (such as: affective flattening, emotional and social withdrawal, decreased expression, language poverty). RISPERDAL® relieves affective symptoms (such as depression, feelings of guilt, etc.) associated with schizophrenia. RISPERDAL® is also effective in maintaining clinical improvement during continued therapy in patients who have responded to initial treatment.